Published: September 2023
The plasmid DNA manufacturing process is fraught with several challenges, including low yield, plasmid instability, and regulatory concerns. As a result, researchers and drug developers are increasingly relying on contract service providers with specialized expertise and advanced technologies for their GMP grade plasmid DNA manufacturing requirements.
To order this 250+ pages report, which features 150+ figures and 160+ tables, please visit Plasmid DNA Manufacturing Market Report
Presently, the market is dominated by mid-sized (having 51-500 employees) and small companies (having 11-50 employees). It is worth noting that majority (~60%) of the firms engaged in this domain are based in North America, followed by Europe (~25%).
Manufacturing and supply agreements emerged as the most popular partnership model adopted by stakeholders engaged in this industry, during the period 2015-2023. Further, most of the intercontinental, as well as intracontinental deals have been inked by players based in North America.
The maximum number of acquisitions related to plasmid DNA were reported in 2020 (~40%). It is worth highlighting that majority of the acquisitions were done for the purpose of geographical expansion.
Nearly 75% of the installed plasmid DNA manufacturing capacity belongs to large and very large players. In addition, 45% of the overall capacity is installed in Asia, followed by North America (30%).
The commercial demand for plasmid DNA, which forms a vital component of cell and gene therapy products, is projected to increase at a CAGR of ~15.21% during forecast period. Further, the current clinical demand for plasmid DNA captures around 40% of the total demand.
By 2035, North America is expected to capture around 45% of the market share, followed by Europe (25%). In terms of therapeutic area, oncological disorders are expected to capture a prominent share of the current and future market.
The financial opportunity within the plasmid DNA manufacturing market has been analyzed across the following segments:
The report features inputs from eminent industry stakeholders, according to whom, growing demand for gene therapy products and increasing trend of outsourcing will drive the growth of third-party service providers engaged in the plasmid DNA manufacturing market, The report includes detailed transcripts of the discussions held with following industry experts:
The research also includes detailed profiles of key players (listed below), featuring a brief overview of the company, details related to its financial information (if available), recent developments (including partnerships and collaborations) and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/plasmid-dna-manufacturing-market.html or email firstname.lastname@example.org
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES